MedTrace Logo

French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome

NCT05308927 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 221

Last updated 2025-09-25

No results posted yet for this study

Summary

This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of Norditropin® as well as Health Related Quality of Life (HRQoL) data. This registry will include the entirety of children treated with Norditropin® for short stature due to NS over the inclusion period. The decision to initiate treatment with commercially available Norditropin® is made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Conditions

  • Noonan Syndrome

Interventions

DRUG

Norditropin

Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency dept. 2834 · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-16
Primary Completion
2028-03-17
Completion
2028-03-17

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05308927 on ClinicalTrials.gov